Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03123497
  4. Details
NCT03123497 Clinical Trial

Assessment of Quality of Life of Children With Chronic Idiopathic Thrombocytopenic Purpura (Kid's ITP Tools)

Idiopathic Thrombocytopenic Purpura Clinical Trial

— KIT  

Official title:
Assessment of Quality of Life of Children With Chronic Idiopathic Thrombocytopenic Purpura

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03123497
Other study ID # 49RC17_0011
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 12, 2017
Est. completion date October 30, 2020

Study information
Verified date March 2020
Source University Hospital, Angers
Contact marianne roumy
Phone 0241356385
Email marianne.roumy@chu-angers.fr
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Assessment of quality of life of patient with chronic idiopathic thrombocytopenic purpura according to the type of treatment

Recruitment information / eligibility
Status Recruiting
Enrollment 183
Est. completion date October 30, 2020
Est. primary completion date October 2020
Accepts healthy volunteers No
Gender All
Age group 1 Year to 17 Years
Eligibility Inclusion Criteria:

- children with Idiopathic thrombocytopenic purpura

- aged between 1 and 17 year

- Idiopathic thrombocytopenic purpura persistent at 12 months

- obtention of informed consent

Exclusion Criteria:

- Persistant/acute Idiopathic thrombocytopenic purpura

- concomittant chronic disease, stabilized or not

- Concomittant disease with life expectancy < 1 year

- Person who have not belong to a social security scheme

- Secondary Idiopathic thrombocytopenic purpura

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• completion of questionnaire
completion of questionnaire for patient and parent

Locations
Country Name City State
France CHU d'Angers Angers

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Angers

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary quality of life score according to type of treatment quality of life score according to type of treatment at inclusion visit
Secondary number of hospitalisation and consults per year number of hospitalisation and consults per year at inclusion visit
Secondary description of general quality of life use ped'sQL general at inclusion visit
Secondary description of general quality of life use ped'sQL fatigue at inclusion visit
Secondary description of awareness of parent and patient about Idiopathic thrombocytopenic purpura use Kid's ITO Tools questionnaire at inclusion visit
See also
  Status Clinical Trial Phase
Completed NCT05220878 - Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP Phase 3
Completed NCT00451594 - High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP Phase 3
Withdrawn NCT01276561 - Single Incision Versus Standard Laparoscopic Splenectomy N/A
Completed NCT01713855 - Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura N/A
Recruiting NCT03465020 - Investigation on a Dynamic Cohort of Italian Patients With Active ITP
Completed NCT00603642 - P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Phase 3
Completed NCT01143038 - Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim Phase 2
Not yet recruiting NCT04128358 - Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind? N/A
Completed NCT00128882 - Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D Phase 2
Completed NCT01525836 - rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP Phase 3
Completed NCT00888901 - Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Phase 4
Completed NCT00828750 - Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Phase 3
Completed NCT00475423 - A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. Phase 2
Completed NCT00625443 - Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003 Phase 2
Completed NCT00454857 - Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) N/A
Completed NCT00102323 - AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy Phase 3
Completed NCT05492409 - Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients Phase 3
Terminated NCT01433978 - A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) Phase 3
Withdrawn NCT01443351 - Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)
Completed NCT01520909 - Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. Phase 3